Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Alcohol is responsible for a significant portion of global disease and death, contributing to 2.6 million deaths annually. It ...

Varshavski: I asked a bunch of different specialists what's the one medical breakthrough they're excited about in their ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Promising new research suggests GLP-1 medications like Ozempic and Wegovy may reduce alcohol cravings and consumption in ...